An Incorrect Quantity Limit Leads to a Tactical Plan That Targets PBMs and Plans

A leading pharmaceutical manufacturer had recently obtained an indication for once daily use (OaD) for erectile dysfunction to supplement its original “as needed (PRN)” indication. With quantity limits (QLs) of 4 to 8 tablets existing on its and similar PRN products, a spillover effect resulted in an accidental blanket QL placed on the drug, even when appropriately prescribed for OaD use. Discover how Precision helped get the QLs reversed.

Get the case study

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.